CN114641564B - 工程化的调节性t细胞 - Google Patents

工程化的调节性t细胞 Download PDF

Info

Publication number
CN114641564B
CN114641564B CN202080076993.4A CN202080076993A CN114641564B CN 114641564 B CN114641564 B CN 114641564B CN 202080076993 A CN202080076993 A CN 202080076993A CN 114641564 B CN114641564 B CN 114641564B
Authority
CN
China
Prior art keywords
tcr
cells
seq
chain
foxp3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202080076993.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114641564A (zh
Inventor
H·施陶斯
S·托马斯
O·普雷汉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201915354A external-priority patent/GB201915354D0/en
Priority claimed from GB201915351A external-priority patent/GB201915351D0/en
Priority claimed from GB201915366A external-priority patent/GB201915366D0/en
Priority claimed from GB201915347A external-priority patent/GB201915347D0/en
Priority claimed from GB201915344A external-priority patent/GB201915344D0/en
Priority claimed from GB201915341A external-priority patent/GB201915341D0/en
Priority claimed from GB201915348A external-priority patent/GB201915348D0/en
Priority claimed from GB201915360A external-priority patent/GB201915360D0/en
Priority claimed from GB201915357A external-priority patent/GB201915357D0/en
Priority claimed from GB201915362A external-priority patent/GB201915362D0/en
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of CN114641564A publication Critical patent/CN114641564A/zh
Application granted granted Critical
Publication of CN114641564B publication Critical patent/CN114641564B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
CN202080076993.4A 2019-10-23 2020-10-22 工程化的调节性t细胞 Expired - Fee Related CN114641564B (zh)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
GB201915344A GB201915344D0 (en) 2019-10-23 2019-10-23 Engineered regulatory T cell
GB1915347.7 2019-10-23
GB201915341A GB201915341D0 (en) 2019-10-23 2019-10-23 Engineered regulatory T cell
GB201915360A GB201915360D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB201915362A GB201915362D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915362.6 2019-10-23
GB1915341.0 2019-10-23
GB201915354A GB201915354D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915348.5 2019-10-23
GB201915351A GB201915351D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB201915357A GB201915357D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915366.7 2019-10-23
GB201915348A GB201915348D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB201915347A GB201915347D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915351.9 2019-10-23
GB1915354.3 2019-10-23
GB1915360.0 2019-10-23
GB201915366A GB201915366D0 (en) 2019-10-23 2019-10-23 Engineered regulatory t cell
GB1915357.6 2019-10-23
GB1915344.4 2019-10-23
PCT/GB2020/052659 WO2021079122A1 (en) 2019-10-23 2020-10-22 Engineered regulatory t cell

Publications (2)

Publication Number Publication Date
CN114641564A CN114641564A (zh) 2022-06-17
CN114641564B true CN114641564B (zh) 2024-07-19

Family

ID=73040143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080076993.4A Expired - Fee Related CN114641564B (zh) 2019-10-23 2020-10-22 工程化的调节性t细胞

Country Status (7)

Country Link
US (1) US20220364057A1 (https=)
EP (1) EP4048294A1 (https=)
JP (1) JP2022553540A (https=)
CN (1) CN114641564B (https=)
AU (1) AU2020370033A1 (https=)
CA (1) CA3154606A1 (https=)
WO (1) WO2021079122A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
EP4568686A2 (en) * 2022-08-12 2025-06-18 Abata Therapeutics, Inc. Cell therapies for multiple sclerosis
WO2024039576A2 (en) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183056A1 (en) * 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2016133779A1 (en) * 2015-02-16 2016-08-25 The Trustees Of The University Of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183056A1 (en) * 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg;Leigh A. Stephens et al.;EUROPEAN JOURNAL OF IMMUNOLOGY;第39卷(第4期);第1108页摘要，第1113页左栏最后一段 *

Also Published As

Publication number Publication date
US20220364057A1 (en) 2022-11-17
CA3154606A1 (en) 2021-04-29
EP4048294A1 (en) 2022-08-31
CN114641564A (zh) 2022-06-17
WO2021079122A1 (en) 2021-04-29
JP2022553540A (ja) 2022-12-23
AU2020370033A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
US20250154532A1 (en) Engineered regulatory t cell
JP7789666B2 (ja) Ｈｌａ特異的なキメラ抗原受容体
CN114641564B (zh) 工程化的调节性t细胞
US20220363733A1 (en) Engineered regulatory t cell
JP2025515116A (ja) 制御性ｔ細胞の抑制活性を維持するための方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240719